Literature DB >> 1656990

20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses.

L Binderup1, S Latini, E Binderup, C Bretting, M Calverley, K Hansen.   

Abstract

The 20-epi-vitamin D3 analogues are a novel class of vitamin D3 derivatives, structurally related to 1 alpha,25-dihydroxycholecalciferol (1 alpha,25(OH)2D3). They are characterized by an altered stereochemistry at carbon 20 in the side-chain. In vitro, these new analogues were found to be considerably more potent as regulators of growth and differentiation in the human histiocytic lymphoma cell line U 937 than 1 alpha,25(OH)2D3, despite a practically unchanged calcemic activity in vivo. The most potent analogue, KH 1060, inhibited cell proliferation by 50% at 10(-12) M (14,000 times more active than 1 alpha,25(OH)2D3). At the same time, KH 1060 induced cell differentiation at concentrations as low as 10(-14)M. In addition, the 20-epi-vitamin D3 analogues were found to be very potent inhibitors of T-lymphocyte proliferation induced by interleukin-1 or alloantigen. In this respect, they were several orders of magnitude more active than the potent immunosuppressive agent cyclosporin A (CyA). KH 1060, the most potent analogue, inhibited interleukin-1-induced mouse thymocyte proliferation by 50% at 3 x 10(-16) M and allogeneic stimulation of mouse spleen lymphocytes at 5 x 10(15) M. These effects were considered to be mediated by inhibition of interleukin-2 release from activated T-lymphocytes. The new analogues are of potential interest in the prevention of graft rejection and in the treatment of psoriasis, cancer and auto-immune diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656990     DOI: 10.1016/0006-2952(91)90426-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

1.  Rapid actions of calcitriol and its side chain analogues CB1093 and GS1500 on intracellular calcium levels in skeletal muscle cells: a comparative study.

Authors:  G Vazquez; J Sellés; A R de Boland; R Boland
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 2.  Structure function studies: identification of vitamin D analogs for the ligand-binding domains of important proteins in the vitamin D-endocrine system.

Authors:  A W Norman; F R Silva
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

3.  Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat.

Authors:  S T Lillevang; J Rosenkvist; C B Andersen; S Larsen; E Kemp; T Kristensen
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Vitamin D receptor expression in colorectal cancer.

Authors:  M G Thomas; P A Sylvester; P Newcomb; R J Longman
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 5.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

6.  A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia.

Authors:  P Larsson; L Mattsson; L Klareskog; C Johnsson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 7.  Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.

Authors:  Jörg Reichrath; Christos C Zouboulis; Thomas Vogt; Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

8.  Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line.

Authors:  M G Thomas; S Tebbutt; R C Williamson
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

Review 9.  Vitamin D3 and skin diseases.

Authors:  K Kragballe
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060.

Authors:  G C van den Bemd; H A Pols; J C Birkenhäger; J P van Leeuwen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.